<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932203</url>
  </required_header>
  <id_info>
    <org_study_id>20130006</org_study_id>
    <nct_id>NCT01932203</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease</brief_title>
  <acronym>Challenge</acronym>
  <official_title>A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inha University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There may be a difference in efficacy of cilostazol and aspirin on progression of white
      matter changes in cerebral small vessel disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the efficacy of aspirin and cilostazol on
      volume of white matter changes in cerebral small vessel disease.

      The secondary objectives are to compare the impact of aspirin and cilostazol on DTI
      parameters, lacune, microbleeds, brain atrophy, cognition, depression, neurologic signs,
      gait, urination, and activities of daily living.

      We also investigate risk factors associated with progression of cerebral small vessel
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 17, 2013</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of white matter changes (WMCs)</measure>
    <time_frame>baseline, week 104</time_frame>
    <description>Measure change of WMC on brain MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean diffusivity (MD) and Fraction Anisotropy (FA) on Diffusion Tensor Imaging</measure>
    <time_frame>baseline and week 104</time_frame>
    <description>High MD and low FA means tissue damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lacunes</measure>
    <time_frame>baseline and week 104</time_frame>
    <description>High number means tissue damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of microbleeds</measure>
    <time_frame>baseline and week 104</time_frame>
    <description>High number means tissue damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain volume and cortical thickness</measure>
    <time_frame>baseline and week 104</time_frame>
    <description>Low score means tissue damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure global cognition. Score range is 0-30. Higher score means good cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive test</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Seoul Verbal Learning Test, Boston Naming test-short form, ROCF copy, animal fluency, phonemic fluency, Stroop test, Digit-symbol test, Trail making test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating scale-sum of boxes</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure global cognition. Score range is 0-18. Higher score means good cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>King's Health Questionnaire</measure>
    <time_frame>baseline, week 42, and week 104</time_frame>
    <description>Measure voiding function. Higher score means bad function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale-Short form</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure depression. Score range is 0-15. Higher score means depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure abnormal behavior. Score range is 0-144. Higher score means severe abnormal behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayer Activities of Daily Living</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure instrumental activities of daily living (ADL). Score range is 1-10. Higher score means bad ADL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure physical ADL. Score range is 0-20. Higher score means good physical ADL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyramidal and Extrapyramidal Scale (PEPS)</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <description>Measure neurologic signs. Score range is 0-60. Higher score means many abnormal neurologic signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed UP and Go (TUG) test</measure>
    <time_frame>basline, week 52, and week 104</time_frame>
    <description>Measure gait. Higher score means bad gait.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>baseline, week 4, 16, 28, 40, 52, 64, 76, 88, and 104</time_frame>
    <description>measure any adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>All ischemic stroke event</measure>
    <time_frame>week 104</time_frame>
    <description>cerebral infarction and transient ischemic attack</description>
  </other_outcome>
  <other_outcome>
    <measure>All vascular events</measure>
    <time_frame>week 104</time_frame>
    <description>including ischemic stroke, transient ischemic attack, myocardial infarction, angina pectoris, cerebral venous thrombosis, pulmonary embolism, symptomatic deep vein thrombosis, symptomatic peripheral artery occlusion, other vascular occlusion, and any revascularization procedure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Cerebral Small Vessel Disease</condition>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin 100mg by mouth once a day for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pletaal SR 200mg by mouth once a day for 104 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>100mg once a day</description>
    <arm_group_label>aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>200mg once a day</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 to 85 years of age

          -  He/She can walk to the hospital (walker or cane is permissible).

          -  Cerebral small vessel disease is observed on brain MRI.

             1) presence of one or more lacunar infarction and 2) moderate or severe confluent
             leukoaraiosis (defined as grade 2 or 3 on a modified Fazekas scale): periventricular
             WMCs with cap or rims lager than 5mm and deep subcortical WMCs &gt;10 mm in maximum
             diameter

          -  written informed consent

        Exclusion Criteria:

          -  Any patient with contraindication of antiplatelets

          -  Any patient with cardioembolic source

          -  Carotid bruit or large cerebral artery stenosis &gt;50%

          -  Cortical infarction or subcortical infarction lager than 1.5 cm

          -  bleeding tendency

          -  chronic liver disease (AST or ALT &gt;100 IL/L)

          -  chronic renal disease (Creatinine &gt;3.0mg/dL)

          -  active gastrointestinal ulcer

          -  any patients with any severe or unstable medical disease that may prevent them from
             completing study requirements (i.e., unstable or severe asthma)

          -  Anemia (Hb &lt;10g/dL) or thrombocytopenia

          -  Cardiac pacemaker or contraindication to MRI

          -  Pregnancy or breast-feeding

          -  drug or alcohol addiction

          -  Any other white matte disease (i.e., Multiple sclerosis, sarcoidosis, or brain
             irradiation, etc) or brain tumor

          -  Parkinson's disease, Alzheimer's disease or any other neurodegenerative disease

          -  any hearing or visual impairment that can disturb the efficient evaluation of the
             patient

          -  recent cerebral infarction with 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong Hye Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>412-270</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongtan Sacred Heart Hospital, Hallym University College of Medicine</name>
      <address>
        <city>Hwaseong-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Iksan Hospital</name>
      <address>
        <city>Iksan</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University School of Medicine</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inha University Hospital</investigator_affiliation>
    <investigator_full_name>Inha University Hospital</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cerebral small vessel disease</keyword>
  <keyword>Leukoaraiosis</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Diffusion Tensor Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

